Kelly Michael 4

What Happened
Kelly Michael, a director of ARS Pharmaceuticals (SPRY), was granted a derivative award of 30,000 shares on 2026-06-24. The reported acquisition price is $0.00 (i.e., no cash paid). This was a grant/award (Form 4 code A), not an open-market purchase or sale—commonly a retention or compensation award rather than a direct bullish purchase.

Key Details

• Transaction date: 2026-06-24; Form 4 filed: 2026-06-26 (timely filing).
• Security: 30,000 derivative shares granted at $0.00 per share (total reported value $0).
• Shares owned after transaction: not specified in the provided filing.
• Footnote: The award vests in full on the earlier of June 24, 2027 or the date of the issuer’s 2027 annual meeting of stockholders.
• Transaction code: A (grant/award). No 10b5-1 plan, tax-withholding, or immediate sale indicated in the disclosed items.

Context
This is a derivative grant (likely restricted stock units or a similar award) that will vest over time; no exercise or immediate sale occurred. Such awards are typically compensation/retention tools for insiders and do not by themselves indicate immediate trading sentiment. The filing appears timely under Form 4 rules.